Going Deeper Into Rare Disease, GSK Takes Reins of Amicus Fabry Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Even with Phase III trial delays, Glaxo pays $60 million upfront for worldwide rights to Amigal and takes a minority stake in its developer.